William T Booth, Noah B Walker, W Todd Lowther, Allyn C Howlett
Journal: Molecules (Basel, Switzerland) 2020;24(20):3672
PMID: 31614728
Cannabinoid receptor interacting protein 1a (CRIP1a) is an important CB cannabinoid receptor-associated protein, first identified from a yeast two-hybrid screen to modulate CB-mediated N-type Ca currents. In this paper we review studies of CRIP1a function and structure based upon in vitro experiments and computational chemistry, which elucidate the specific mechanisms for the interaction of CRIP1a with CB receptors. N18TG2 neuronal cells overexpressing or silencing CRIP1a highlighted the ability of CRIP1 to regulate cyclic adenosine 3',5'monophosphate (cAMP) production and extracellular signal-regulated kinase (ERK1/2) phosphorylation. These studies indicated that CRIP1a attenuates the G protein signaling cascade through modulating which Gi/o subtypes interact with the CB receptor. CRIP1a also attenuates CB receptor internalization via β-arrestin, suggesting that CRIP1a competes for β-arrestin binding to the CB receptor. Predictions of CRIP1a secondary structure suggest that residues 34-110 are minimally necessary for association with key amino acids within the distal C-terminus of the CB receptor, as well as the mGlu metabotropic glutamate receptor. These interactions are disrupted through phosphorylation of serines and threonines in these regions. Through investigations of the function and structure of CRIP1a, new pharmacotherapies based upon the CRIP-CB receptor interaction can be designed to treat diseases such as epilepsy, motor dysfunctions and schizophrenia.
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.